Last reviewed · How we verify
GSK Biologicals' quadrivalent influenza vaccine
GSK Biologicals' quadrivalent influenza vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | GSK Biologicals' quadrivalent influenza vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers. (PHASE2)
- Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX) (PHASE2)
- Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age (PHASE3)
- A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years (PHASE1)
- Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children (PHASE2)
- An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Biologicals' quadrivalent influenza vaccine CI brief — competitive landscape report
- GSK Biologicals' quadrivalent influenza vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK Biologicals' quadrivalent influenza vaccine
What is GSK Biologicals' quadrivalent influenza vaccine?
GSK Biologicals' quadrivalent influenza vaccine is a Biologic drug developed by GlaxoSmithKline.
Who makes GSK Biologicals' quadrivalent influenza vaccine?
GSK Biologicals' quadrivalent influenza vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is GSK Biologicals' quadrivalent influenza vaccine in?
GSK Biologicals' quadrivalent influenza vaccine is in Phase 1.